Compare · ACHV vs IDXX
ACHV vs IDXX
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $44.27B, about 78.7x ACHV ($562.6M).
- Over the past year, ACHV is up 46.3% and IDXX is up 8.1% - ACHV leads by 38.2 points.
- ACHV has been more active in the news (10 items in the past 4 weeks vs 5 for IDXX).
- IDXX has more recent analyst coverage (23 ratings vs 8 for ACHV).
- Company
- Achieve Life Sciences Inc.
- IDEXX Laboratories Inc.
- Price
- $5.49+7.13%
- $561.97-0.07%
- Market cap
- $562.6M
- $44.27B
- 1M return
- +14.39%
- -1.85%
- 1Y return
- +46.27%
- +8.09%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 10
- 5
- Recent ratings
- 8
- 23
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest ACHV
- SEC Form DEF 14A filed by Achieve Life Sciences Inc.
- SEC Form 4 filed by Director Waldman Reid Alexander
- SEC Form 4 filed by Director Farrow Jeffrey S
- New insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)
- New insider Farrow Jeffrey S claimed no ownership of stock in the company (SEC Form 3)
- Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update
- Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
- SEC Form PRE 14A filed by Achieve Life Sciences Inc.
- SEC Form EFFECT filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
Latest IDXX
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.
- IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
- IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
- The Biology Came First.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Samad Sam
- SEC Form 4 filed by Director Vandebroek Sophie V.
- SEC Form 4 filed by Director Peacock Karen
- SEC Form 4 filed by Director Junius Daniel M